A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Epilepsy is a non-communicable central nervous system disorder that affects over 60 million people worldwide. The developments in epilepsy treatment face major hurdles due to drug resistance and disease recurrence after reduction in medication. Nano-technological anti-epileptic drug (AED) delivery systems have recently garnered attention due to their ability to cross the blood brain barrier, improved selectivity and potential for sustained drug delivery to the brain. This review focuses on several nano-based AED delivery systems, including liposomes, nano-emulsions, polymeric nanoparticles, solid-lipid nanoparticles and magnetic nanoparticles. Their limitations and future prospects in terms of AED delivery to the brain are also highlighted. It is hoped that the present communication will be helpful in the identification of potential AED delivery systems based on their advantages and disadvantages.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Astrocyte-endothelial Interactions and Blood-Brain Barrier Permeability*
Abbott, N. J. (2002) · Journal of Anatomy · doi:10.1046/j.1469-7580.2002.00064.x · Cited by 1,168
In vitro and in vivo degradation of porous poly(dl-lactic-co-glycolic acid) foams
Lu, L., Peter, S. J., D. Lyman, M., Lai, H.-L., Leite, S. M., Tamada, J. A., Uyama, S., Vacanti, J. P., Langer, R., & Mikos, A. G. (2000) · Biomaterials · doi:10.1016/s0142-9612(00)00047-8 · Cited by 668
Thorne, R. G., & Nicholson, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509425103 · Cited by 641 · cited 1×
“For example, the size of the NPs is a very important determinant for its efficiency in crossing the BBB; NPs ranging from 35 to 64 nm easily access most neural tissues [12].”
BackgroundNanoemulsion components screening and selection: A technical note
Azeem, A., Rizwan, M., Ahmad, F. J., Iqbal, Z., Khar, R. K., Aqil, M., & Talegaonkar, S. (2009) · AAPS PharmSciTech · doi:10.1208/s12249-008-9178-x · Cited by 567
Solid lipid nanoparticles for targeted brain drug delivery.
BLASI, P., GIOVAGNOLI, S., SCHOUBBEN, A., RICCI, M., & ROSSI, C. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.011 · Cited by 506
Intranasal nanoemulsion based brain targeting drug delivery system of risperidone
Kumar, M., Misra, A., Babbar, A. K., Mishra, A. K., Mishra, P., & Pathak, K. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.03.029 · Cited by 435 · cited 1×
“(2008) reported that an optimized olanzapineloaded NE formulation gave better nose-to-brain delivery than an olanzapine solution in a rat model [107].”
BackgroundPandey, R., & Khuller, G. K. (2005) · Tuberculosis · doi:10.1016/j.tube.2004.11.003 · Cited by 318 · cited 2×
“Several studies have reported on different SLN formulations that may be administered via different routes, including the parenteral, oral, rectal, ophthalmic and topical routes, which leads to controlled delivery and enhanced bioavailability of the entrapped drugs [74-79].”
BackgroundCNS Drug Delivery Systems: Novel Approaches
Pathan, S., Iqbal, Z., Zaidi, S., Talegaonkar, S., Vohra, D., Jain, G., Azeem, A., Jain, N., Lalani, J., Khar, R., et al. (2009) · Recent Patents on Drug Delivery & Formulation · doi:10.2174/187221109787158355 · Cited by 193 · cited 1×
“use of liposomal carriers [31].”
Self-citationBondì, M. L., Craparo, E. F., Giammona, G., & Drago, F. (2010) · Nanomedicine · doi:10.2217/nnm.09.67 · Cited by 175
Hsiao, M.-H., Larsson, M., Larsson, A., Evenbratt, H., Chen, Y.-Y., Chen, Y.-Y., & Liu, D.-M. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.05.038 · Cited by 104
Cited by
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
Jiao, Y., Yang, L., Wang, R., Song, G., Fu, J., Wang, J., Gao, N., & Wang, H. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16121611 · Cited by 63
“SLNs can be used as carriers for CNS diseases, such as AD [187], PD [188], HD [189], MS [190], epilepsy [191], ischemic stroke [192], brain tumors [193], and cancers.”
Metadata
- Authors
- Jabir, N., Tabrez, S., Firoz, C. K., Zaidi, S., Baeesa, S., Gan, S., Shakil, S., & Kamal, M.
- Venue
- Current Drug Metabolism
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-09-28
- Volume
- 16
- Issue
- 5
- Pages
- 336-345
- ISSN
- 1389-2002 (ISSN-L)
- OpenAlex
- W2168269378
- Cited by
- 35
- References
- 10
- FWCI
- 0.23
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications. https://app.cochat.ai/papers/10.2174/1389200215666141125142605
- The paper
- Jabir, N., Tabrez, S., Firoz, C. K., Zaidi, S., Baeesa, S., Gan, S., Shakil, S., & Kamal, M. (2015). A Synopsis of Nano-Technological Approaches Toward Anti-Epilepsy Therapy: Present and Future Research Implications. Current Drug Metabolism. https://doi.org/10.2174/1389200215666141125142605
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.